Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study

详细信息    查看全文

• 作者：Robert W. Frenck Jr^a ; ^{robert.frenck@cchmc.org} ; C. Buddy Creech^b ; Eric A. Sheldon^c ; ¹ ; ⁴ ; David J. Seiden^d ; Martin K. Kankam^e ; James Baber^f ; Edward Zito^g ; ² ; ⁴ ; Robin Hubler^g ; Joseph Eiden^h ; Joseph M. Severs^h ; Shite Sebastian^h ; Jasdeep Nanra^h ; Kathrin U. Jansen^h ; William C. Gruber^h ; Annaliesa S. Anderson^h ; Douglas Girgenti^h ; ³ ; ⁴
• 关键词：Staphylococcus aureus ; Vaccine ; Functional antibodies ; Capsular polysaccharide ; Clumping factor A ; Manganese transporter C
• 刊名：Vaccine
• 出版年：2017
• 出版时间：5 January 2017
• 年：2017
• 卷：35
• 期：2
• 页码：375-384
• 全文大小：680 K
• 卷排序：35

文摘

SA4Ag is a novel multiantigen vaccine that targets S. aureus virulence factors. A single dose of SA4Ag was well-tolerated in healthy adults aged 18–64 years. A robust functional immune response was elicited to each vaccine component. Antibody rise was rapid and sustained after one dose of SA4Ag vaccine. SA4Ag is a promising candidate vaccine to prevent invasive S. aureus infections.